Daina B. Esposito, MPH, PhD

Executive Director, Global Safety Epidemiology
Moderna

Poster(s):

• (C-017) Changes in the incidence of adverse events of special interest after diagnosis of COVID-19 between November 2020 and January 2024
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET

• (SLC-055) Clinical course and outcomes of myocarditis/pericarditis cases following mRNA-1273 vaccination compared to cases not following COVID-19 vaccination: interim analysis of a VAC4EU cohort study
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• (A-266) Feasibility Assessment of Using National Administrative Databases (SISPRO) to Support Post-Authorization Vaccine Safety Studies in Colombia
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-252) Incidence of Outcomes Relevant to Vaccine Safety Monitoring in a General Population, After Influenza Vaccination, and After Respiratory Infections in US Claims Data from August 1, 2022 to July 31, 2023
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-332) Monitoring safety of Moderna COVID-19 vaccines in pregnancy: a multi-database study in Denmark, Norway, Spain and the United Kingdom. A regulator-mandated postauthorisation safety study in the VAC4EU network (EUPAS44450).
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (A-217) Observed rate of safety outcomes, vaccinations, and healthcare utilization in elderly persons with Commercial vs Medicare Advantage insurance in a US Claims Database
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• (SLC-054) Risk factors for myocarditis/pericarditis following mRNA-1273 vaccination: interim analysis of a VAC4EU case-cohort study
  Tuesday, August 26, 2025

  12:15 PM - 1:15 PM ET

• (A-260) Safety of Moderna’s Omicron-Containing Bivalent and XBB1.5- containing Monovalent Vaccines: Results from a US Claims Database Cohort Study
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET